Insider Selling: Insmed (NASDAQ:INSM) Insider Sells 1,396 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 1,396 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total transaction of $241,968.68. Following the completion of the sale, the insider directly owned 58,799 shares of the company’s stock, valued at $10,191,630.67. The trade was a 2.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $124,124.63.
• On Monday, November 3rd, Michael Alexander Smith sold 27,130 shares of Insmed stock. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40.

Insmed Stock Down 3.3%

NASDAQ INSM traded down $5.73 during midday trading on Thursday, hitting $170.27. 2,588,589 shares of the company traded hands, compared to its average volume of 2,142,398. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The company’s 50-day simple moving average is $190.79 and its 200-day simple moving average is $151.24. The company has a market cap of $36.31 billion, a PE ratio of -27.51 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company’s revenue was up 52.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.27) earnings per share. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Guggenheim cut their price objective on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. HC Wainwright lowered their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Cantor Fitzgerald lifted their price target on shares of Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Truist Financial initiated coverage on Insmed in a report on Friday, December 19th. They set a “buy” rating and a $202.00 price objective for the company. Finally, TD Cowen lowered their price objective on Insmed from $269.00 to $241.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $205.64.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of INSM. Royal Bank of Canada raised its holdings in shares of Insmed by 33.2% in the first quarter. Royal Bank of Canada now owns 245,262 shares of the biopharmaceutical company’s stock worth $18,710,000 after buying an additional 61,190 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Insmed by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company’s stock valued at $8,364,000 after acquiring an additional 4,176 shares during the period. Caxton Associates LLP purchased a new position in Insmed in the 1st quarter worth $441,000. Woodline Partners LP lifted its position in Insmed by 53.3% during the 1st quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock worth $18,979,000 after acquiring an additional 86,540 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Insmed by 10.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock worth $41,157,000 after acquiring an additional 52,637 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.